Boceprevir - PowerPoint PPT Presentation

Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions

Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions. C Kasserra, E Hughes, M Treitel, S Gupta, and E O'Mara International Conference on Viral Hepatitis April 11, 2011 Baltimore, MA. Disclosure Statement. Full time employee of Merck and Co.

★ ★ ★ ★ ★

200 views • 17 slides

T. Poynard , MD

Interim Results from HCV SPRINT-1 Phase 2 Study of Boceprevir Plus Peginterferon alfa-2b/ Ribavirin in Treatment-Naïve Subjects with Genotype-1 CHC. T. Poynard , MD. Luis Balart Thomas Boyer Robert Brown William Cassidy Raymond Chung Gary Davis Mitchell Davis Steven Flamm

★ ★ ★ ★ ★

287 views • 16 slides

SPRINT-1 Study Design

PART 1. PART 2 a. SPRINT-1 Study Design. Week 28. Week 4. Week 48. Peg-IFN  2b 1.5 μ g/kg + RBV 800-1400 mg for 48 wks . 24 wks Follow-up. N=104. Control. 44 wks Follow-up. Peg-IFN  2b + RBV 800-1400 mg. Peg-IFN  2b 1.5 μ g/kg + RBV 800-1400mg +

★ ★ ★ ★ ★

289 views • 1 slides

View Boceprevir PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Boceprevir PowerPoint presentations. You can view or download Boceprevir presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.